Overview

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Chipscreen Biosciences, Ltd.

Treatments:

Chiauranib
Paclitaxel